Alterity Therapeutics Reports Cessation of Securities
Ticker: PRNAF · Form: 6-K · Filed: May 23, 2024 · CIK: 1131343
| Field | Detail |
|---|---|
| Company | Alterity Therapeutics Ltd (PRNAF) |
| Form Type | 6-K |
| Filed Date | May 23, 2024 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: securities-cessation, filing-update, foreign-issuer
Related Tickers: ATH
TL;DR
ATH securities are ceasing, check your holdings.
AI Summary
Alterity Therapeutics Limited filed a Form 6-K on May 23, 2024, to report the cessation of its securities, identified as ATH. This filing is incorporated by reference into several of the company's existing registration statements on Form S-8 and Form F-3.
Why It Matters
The cessation of securities can impact investors' ability to trade the company's stock and may signal a change in the company's structure or strategy.
Risk Assessment
Risk Level: medium — Cessation of securities can lead to liquidity issues and uncertainty for investors.
Key Players & Entities
- Alterity Therapeutics Limited (company) — Registrant
- ATH (company) — Securities identifier
- May 23, 2024 (date) — Filing date
- Form 6-K (document) — Filing type
- Form S-8 (document) — Incorporated registration statement
- Form F-3 (document) — Incorporated registration statement
FAQ
What is the primary purpose of this Form 6-K filing?
The primary purpose of this Form 6-K filing is to report the cessation of Alterity Therapeutics Limited's securities, identified as ATH.
When was this Form 6-K filed?
This Form 6-K was filed on May 23, 2024.
What does 'cessation of securities' mean in this context?
In this context, 'cessation of securities' refers to the termination or ending of the company's securities, likely impacting their trading status.
Which registration statements is this 6-K incorporated into?
This 6-K is incorporated by reference into Alterity Therapeutics Limited's Registration Statements on Form S-8 (Files No. 333-251073, 333-248980 and 333-228671) and Form F-3 (Files No. 333-274816, 333-251647, 333-231417 and 333-250076).
What is the company's principal executive office address?
The company's principal executive office is located at Level 14, 350 Collins Street, Melbourne, Victoria 3000, Australia.
Filing Stats: 191 words · 1 min read · ~1 pages · Grade level 11.9 · Accepted 2024-05-22 20:35:21
Filing Documents
- ea0206677-6k_alterity.htm (6-K) — 14KB
- ea020667701ex99-1_alterity.htm (EX-99.1) — 27KB
- ex99-1_001.jpg (GRAPHIC) — 1KB
- 0001213900-24-046048.txt ( ) — 44KB
From the Filing
OF FOREIGN PRIVATE ISSUER SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2024 Alterity Therapeutics Limited (Name of Registrant) Level 14, 350 Collins Street, Melbourne, Victoria 3000 Australia (Address of Principal Executive Office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F Form 40-F This Form 6-K is being incorporated by reference into our Registration Statement on Form S-8 (Files No. 333-251073 , 333-248980 and 333-228671 ) and our Registration Statements on Form F-3 (Files No. 333-274816 , 333-251647 , 333-231417 and 333-250076 ) ALTERITY THERAPEUTICS LIMITED (a development stage enterprise) The following exhibits are submitted: 99.1 Notification of cessation of securities - ATH 1 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Alterity Therapeutics Limited By: /s/ Geoffrey P. Kempler Geoffrey P. Kempler Chairman Date: May 22, 2024 2